lipoc(No B12)

Lipoc (No B12) Peptide: Comprehensive Research Guide

Lipoc (No B12) is a specialized lipolytic peptide formulation designed for research into fat metabolism, body composition optimization, and metabolic health. As the name suggests, this formulation contains the core lipolytic peptide blend without the addition of vitamin B12, making it suitable for researchers who wish to study the effects of the peptide blend independently, or who prefer to control B12 supplementation separately. Lipoc formulations are typically composed of a synergistic blend of peptides and compounds that work together to stimulate lipolysis (fat breakdown), inhibit lipogenesis (fat formation), and improve overall metabolic function, with applications in obesity research, body composition studies, sports science, and metabolic disorder research.

The exact composition of Lipoc formulations can vary, but they typically include a combination of lipolytic peptides such as AOD9604 (a growth hormone fragment with selective fat-burning effects), melanotan peptides (which can increase energy expenditure and reduce appetite), and other metabolic modulators, along with supporting compounds such as L-carnitine (which facilitates fatty acid transport into mitochondria for oxidation), and sometimes B vitamins (including B12, which is essential for energy metabolism and methylation). The “No B12” variant provides the core lipolytic peptide blend without vitamin B12, allowing for greater experimental control and flexibility. Researchers worldwide utilize high-purity Lipoc (No B12) to investigate adipose tissue biology, lipolysis mechanisms, obesity treatment, body composition optimization, metabolic syndrome, and the therapeutic potential of lipolytic peptide blends for a wide range of metabolic conditions.

Molecular Composition and Biological Properties

Lipoc (No B12) is a specialized peptide blend with a composition designed for synergistic lipolytic activity. Key properties:

• COMPOSITION: Specialized blend of lipolytic peptides and metabolic compounds, typically including AOD9604 (Tyr-hGH 177-191), melanocortin peptides, L-carnitine, and other metabolic modulators, without added vitamin B12
• KEY ACTIVE PEPTIDES: AOD9604 (16-amino acid growth hormone fragment, the primary lipolytic component), and potentially other lipolytic/metabolic peptides depending on the specific formulation
• SUPPORTING COMPOUNDS: L-carnitine (amino acid derivative that facilitates fatty acid transport into mitochondria), and potentially other metabolic cofactors
• MOLECULAR WEIGHT: Mixed composition, with primary peptide components ranging from ~1.8 kDa (AOD9604) to larger peptides
• APPEARANCE: White to off-white lyophilized powder
• SOLUBILITY: Soluble in water, PBS, bacteriostatic water, and physiological saline
• pI: Mixed (varies by component; AOD9604 is basic, L-carnitine is zwitterionic)
• BIOAVAILABILITY: Good subcutaneous bioavailability for peptide components; L-carnitine has good oral and parenteral bioavailability
• STABILITY: Stable in lyophilized form when stored properly; peptide components should be protected from light, extreme pH, and proteases
• B12 CONTENT: No added vitamin B12 (this is the defining feature of the “No B12” formulation)

Mechanism of Action and Lipolytic Effects

Lipoc (No B12) exerts its metabolic effects through the combined actions of its multiple components, which work synergistically to promote fat breakdown, inhibit fat storage, and improve metabolic function. Key mechanisms include:

• AOD9604-MEDIATED LIPOLYSIS: The primary lipolytic component of Lipoc (No B12) is typically AOD9604 (Tyr-hGH 177-191), a 16-amino acid peptide fragment of human growth hormone that has been shown to selectively stimulate lipolysis (breakdown of triglycerides into free fatty acids and glycerol) and inhibit lipogenesis (de novo fat synthesis), without the growth-promoting, IGF-1-stimulating, or diabetogenic effects of full-length hGH. AOD9604 appears to act directly on adipose tissue, particularly visceral (abdominal) fat, through mechanisms that may involve activation of hormone-sensitive lipase (HSL) and adipose triglyceride lipase (ATGL), inhibition of lipogenic enzymes (fatty acid synthase, acetyl-CoA carboxylase), and modulation of adipocyte metabolism. Its selective lipolytic effects make it a valuable component of lipolytic peptide blends.
• L-CARNITINE-MEDIATED FATTY ACID OXIDATION: L-carnitine is an amino acid derivative that plays a critical role in energy metabolism by facilitating the transport of long-chain fatty acids from the cytoplasm into the mitochondria, where they can be oxidized (burned) for energy production via beta-oxidation. By increasing fatty acid transport into mitochondria, L-carnitine enhances the utilization of fat as an energy source, particularly during exercise or caloric restriction, and may help reduce fat accumulation by increasing fat oxidation. L-carnitine also has antioxidant effects, supports mitochondrial function, and may improve exercise performance and recovery. Its inclusion in Lipoc (No B12) complements the lipolytic effects of AOD9604 by ensuring that the free fatty acids released by lipolysis are efficiently transported into mitochondria for oxidation, rather than being re-esterified and stored as fat.
• POTENTIAL MELANOCORTIN EFFECTS (if included): Some Lipoc formulations may include melanocortin peptides (such as Melanotan 2 or related compounds) that activate melanocortin receptors (particularly MC4R in the hypothalamus), leading to reduced appetite, increased energy expenditure, increased thermogenesis, and increased fat oxidation. If included, these components provide additional metabolic benefits through central regulation of energy balance, complementing the peripheral lipolytic effects of AOD9604 and L-carnitine. However, the specific composition of Lipoc formulations can vary, and researchers should verify the exact components of the specific formulation they are using.
• SYNERGISTIC EFFECTS OF THE BLEND: The key advantage of a blended formulation like Lipoc (No B12) is the potential for synergistic effects between its components, where the combined effect is greater than the sum of the individual effects. For example: AOD9604 stimulates the breakdown of stored fat (lipolysis), releasing free fatty acids into the bloodstream; L-carnitine then facilitates the transport of these free fatty acids into mitochondria, where they are burned for energy (beta-oxidation); if melanocortin peptides are included, they increase energy expenditure and thermogenesis, increasing the demand for fatty acid oxidation and further promoting fat loss. This coordinated attack on fat metabolism—from breakdown to transport to oxidation—can produce more effective fat loss than any single component alone. In addition, the components may have complementary effects on other aspects of metabolic health, including insulin sensitivity, lipid profiles, and energy levels.
• SELECTIVE VISCERAL FAT REDUCTION: AOD9604, the primary lipolytic component, has been shown to have a preferential effect on visceral (abdominal) adipose tissue, which is the fat depot most strongly associated with metabolic complications (insulin resistance, type 2 diabetes, dyslipidemia, cardiovascular disease). The selective reduction of visceral fat is a particularly desirable feature, as visceral fat accumulation is a key component of metabolic syndrome and is associated with increased health risks, while subcutaneous fat may have some protective metabolic effects. L-carnitine may also preferentially enhance fat oxidation during exercise, particularly in individuals with high visceral fat levels. The combination of these effects may make Lipoc (No B12) particularly useful for research on central obesity and metabolic syndrome.
• MINIMAL EFFECTS ON GROWTH AND IGF-1: Unlike full-length human growth hormone, which stimulates IGF-1 production, promotes linear growth, and can cause insulin resistance and other side effects, the AOD9604 component in Lipoc (No B12) is a small C-terminal fragment of hGH that does not significantly bind to or activate the growth hormone receptor at typical research concentrations, and therefore does not stimulate IGF-1 production, promote growth, or cause the side effects associated with full-length hGH therapy (acromegaly, insulin resistance, edema, joint pain). This selective lipolytic activity, combined with L-carnitine’s excellent safety profile, makes Lipoc (No B12) a potentially safer alternative to hGH for fat loss and body composition research, with fewer systemic side effects.

Research Applications

1. Obesity and Weight Management Research

Lipoc (No B12) is studied in obesity research for its combined lipolytic and metabolic effects:

• Fat Mass Reduction and Weight Loss: Research into Lipoc (No B12) for reducing fat mass and body weight through the combined effects of stimulated lipolysis (AOD9604), enhanced fatty acid oxidation (L-carnitine), and potentially reduced appetite and increased energy expenditure (if melanocortin components are included). In preclinical studies, the individual components of Lipoc (No B12) have been shown to reduce body weight and fat mass, particularly visceral fat, without significant effects on lean body mass or food intake (for AOD9604 and L-carnitine). The blended formulation may produce additive or synergistic effects on fat loss, potentially greater than any single component alone. Research is investigating the optimal dosing, timing, and duration of treatment, the effects on different fat depots (visceral vs. subcutaneous), and the potential for combination with caloric restriction or exercise to enhance fat loss.
• Visceral Adipose Tissue Reduction: Studies investigating Lipoc (No B12)’s preferential effects on visceral (abdominal) adipose tissue, which is the fat depot most strongly associated with metabolic complications. Visceral fat accumulation is a key feature of central obesity and metabolic syndrome, and is associated with increased risk of type 2 diabetes, cardiovascular disease, dyslipidemia, hypertension, and certain cancers. The AOD9604 component has been shown to preferentially reduce visceral fat in animal models, potentially due to differences in receptor expression, blood flow, or metabolic activity between visceral and subcutaneous adipose tissue. L-carnitine may also preferentially enhance fat oxidation during exercise, particularly in individuals with high visceral fat levels. The selective reduction of visceral fat is a particularly desirable feature, as it may provide greater metabolic benefits than overall weight loss alone. Research using dual-energy X-ray absorptiometry (DXA), magnetic resonance imaging (MRI), and computed tomography (CT) is investigating the effects of Lipoc (No B12) on visceral and subcutaneous fat distribution and the relationship between visceral fat reduction and improvements in metabolic health.
• Body Composition and Lean Mass Preservation: Research into Lipoc (No B12)’s effects on body composition, including fat mass, lean body mass, bone mineral density, and body water distribution. One of the challenges of weight loss is the loss of lean body mass (muscle) along with fat mass, which can reduce metabolic rate, increase the risk of weight regain, and impair physical function. The AOD9604 component appears to primarily reduce fat mass with minimal effects on lean body mass, due to its selective effects on adipose tissue and lack of growth-promoting or catabolic effects. L-carnitine has been shown to support muscle function and may help preserve lean mass during caloric restriction by enhancing fat oxidation and reducing muscle protein breakdown. The combination of these effects may make Lipoc (No B12) particularly useful for research on body composition optimization, where the goal is to reduce fat mass while preserving or increasing lean body mass. Research using DXA, MRI, bioelectrical impedance analysis (BIA), and other body composition techniques is investigating the effects of Lipoc (No B12) on body composition and the optimal strategies to maximize fat loss while preserving lean mass.
• Combination with Diet and Exercise: Studies investigating Lipoc (No B12) in combination with caloric restriction (diet) and/or exercise for enhanced fat loss and body composition optimization. Diet and exercise are the foundation of any weight loss program, but many individuals struggle to achieve and maintain their desired body composition with lifestyle interventions alone. Lipoc (No B12)’s lipolytic and metabolic effects may complement diet and exercise by: (1) enhancing the breakdown of stored fat, particularly stubborn visceral fat that is resistant to diet and exercise; (2) increasing fatty acid oxidation, particularly during exercise, enhancing the fat-burning effects of physical activity; (3) potentially increasing energy expenditure and thermogenesis (if melanocortin components are included), increasing overall calorie burning; (4) preserving lean body mass during caloric restriction, helping maintain metabolic rate and physical function. Research is investigating the optimal combination of Lipoc (No B12) with different types of exercise (aerobic, resistance, high-intensity interval training), different dietary patterns (caloric restriction, ketogenic, Mediterranean, high-protein), and different timing strategies (pre-exercise, post-exercise, fasting) to maximize fat loss and body composition improvements.

2. Metabolic Syndrome and Insulin Resistance Research

Lipoc (No B12) is studied in metabolic syndrome research for its effects on visceral fat, insulin sensitivity, and metabolic health:

• Insulin Sensitivity and Glucose Homeostasis: Research into Lipoc (No B12)’s effects on insulin sensitivity, glucose tolerance, fasting blood glucose, postprandial glucose, and overall glucose homeostasis. Insulin resistance (reduced responsiveness of tissues to insulin) is a key feature of metabolic syndrome and type 2 diabetes, and is strongly associated with visceral fat accumulation. Lipoc (No B12)’s reduction of visceral fat may improve insulin sensitivity by reducing lipotoxicity (toxic effects of excess lipids on insulin-sensitive tissues), reducing inflammation, and improving overall metabolic health. The AOD9604 component, unlike full-length hGH, does not cause insulin resistance and may actually improve insulin sensitivity through its effects on reducing visceral fat. L-carnitine has been shown to improve insulin sensitivity and glucose tolerance in some studies, particularly in individuals with insulin resistance or type 2 diabetes, potentially through its effects on reducing intramyocellular lipid accumulation and improving mitochondrial function. Research using hyperinsulinemic-euglycemic clamps (the gold standard for measuring insulin sensitivity), oral glucose tolerance tests (OGTT), insulin tolerance tests (ITT), and homeostasis model assessment (HOMA) is investigating the effects of Lipoc (No B12) on insulin sensitivity and glucose homeostasis in animal models of obesity, insulin resistance, and type 2 diabetes.
• Metabolic Syndrome Features: Studies investigating Lipoc (No B12)’s effects on the multiple features of metabolic syndrome, including central obesity (visceral fat accumulation), insulin resistance/glucose intolerance, hypertension (high blood pressure), dyslipidemia (abnormal lipid levels), and pro-inflammatory/pro-thrombotic states. Metabolic syndrome is a cluster of metabolic abnormalities that significantly increase the risk of type 2 diabetes, cardiovascular disease, and all-cause mortality, and affects a large proportion of the global population. Lipoc (No B12)’s effects on visceral fat reduction, insulin sensitivity, lipid profiles (via L-carnitine and AOD9604), and potentially blood pressure and inflammation may address multiple features of metabolic syndrome simultaneously. The “No B12” formulation allows researchers to study the effects of the peptide blend independently of B12, which is itself an important modulator of homocysteine levels and cardiovascular health. Research is investigating whether Lipoc (No B12) can improve the overall metabolic profile of individuals with metabolic syndrome, and whether these improvements are due to visceral fat reduction or direct effects of the individual components on metabolic pathways.
• Dyslipidemia and Lipid Metabolism: Research into Lipoc (No B12)’s effects on lipid profiles, including total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, non-HDL cholesterol, apolipoprotein B (ApoB), and other lipid parameters. Dyslipidemia (abnormal lipid levels), particularly elevated triglycerides, elevated LDL cholesterol, and reduced HDL cholesterol, is common in individuals with obesity, metabolic syndrome, and type 2 diabetes, and is a major risk factor for cardiovascular disease. The AOD9604 component’s effects on fat metabolism, including stimulation of lipolysis and inhibition of lipogenesis, may improve lipid profiles by reducing triglyceride synthesis and secretion, increasing fatty acid oxidation, and reducing overall fat mass. L-carnitine has been shown to reduce triglyceride levels, increase HDL cholesterol, and improve overall lipid profiles in some studies, particularly in individuals with dyslipidemia or cardiovascular disease, potentially through its effects on enhancing fatty acid oxidation and reducing hepatic triglyceride synthesis. Research using lipid profiling, lipoprotein subclass analysis, and in vitro hepatocyte and adipocyte models is investigating the effects of Lipoc (No B12) on lipid metabolism and dyslipidemia.
• Hepatic Steatosis and Non-Alcoholic Fatty Liver Disease (NAFLD): Studies investigating Lipoc (No B12)’s effects on hepatic steatosis (fat accumulation in the liver), non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH). NAFLD is characterized by excessive accumulation of triglycerides in hepatocytes (liver cells), and is strongly associated with obesity, insulin resistance, metabolic syndrome, and type 2 diabetes. The AOD9604 component’s inhibition of lipogenesis may reduce hepatic fat synthesis, while its stimulation of lipolysis and L-carnitine’s enhancement of fatty acid oxidation may reduce hepatic fat accumulation, potentially improving NAFLD. In addition, Lipoc (No B12)’s reduction of visceral fat and improvement of insulin sensitivity may indirectly reduce hepatic fat accumulation. Research using liver histology, magnetic resonance spectroscopy (MRS), liver enzyme measurements, and in vitro hepatocyte models is investigating the effects of Lipoc (No B12) on hepatic steatosis and NAFLD/NASH. The “No B12” formulation is particularly useful for this research, as B12 itself can affect liver function and homocysteine metabolism, and researchers may wish to control for its effects independently.

3. Sports Performance and Exercise Science Research

Lipoc (No B12) is studied in sports performance and exercise science for its effects on fat metabolism, energy production, and body composition:

• Fat Oxidation During Exercise: Research into Lipoc (No B12)’s effects on fat oxidation during exercise, including the rate of fat burning, the contribution of fat to total energy expenditure, and the crossover point (the exercise intensity at which carbohydrate becomes the dominant fuel source). The L-carnitine component is well-known for its role in fatty acid transport into mitochondria, and supplementation has been shown to increase fat oxidation during exercise, particularly at moderate exercise intensities, and to reduce the reliance on carbohydrate as a fuel source. The AOD9604 component’s stimulation of lipolysis increases the availability of free fatty acids for oxidation, potentially further enhancing fat burning during exercise. If melanocortin components are included, they may increase energy expenditure and thermogenesis, further increasing fat oxidation. The combination of these effects may make Lipoc (No B12) particularly useful for research on enhancing fat oxidation during exercise, which is of interest for endurance performance (by sparing glycogen) and for body composition optimization (by increasing fat burning during workouts). Research using indirect calorimetry, stable isotope tracers (to measure fatty acid oxidation), and exercise performance tests is investigating the effects of Lipoc (No B12) on fat oxidation and fuel utilization during different types and intensities of exercise.
• Exercise Performance and Endurance: Studies investigating Lipoc (No B12)’s effects on exercise performance, including endurance capacity, time to exhaustion, power output, and recovery. L-carnitine supplementation has been shown to improve exercise performance and endurance in some studies, particularly in endurance athletes and during prolonged exercise, potentially by enhancing fat oxidation (sparing glycogen), reducing lactate accumulation, improving mitochondrial function, and reducing muscle damage and oxidative stress. The AOD9604 component’s effects on reducing fat mass may improve power-to-weight ratio and endurance performance, particularly in weight-sensitive sports. If melanocortin components are included, they may increase energy expenditure and potentially improve exercise performance, although they may also cause side effects that could impair performance. Research using exercise performance tests (time trials, time to exhaustion, VO2max testing), blood lactate measurements, and muscle biopsy techniques is investigating the effects of Lipoc (No B12) on exercise performance, endurance, and the underlying physiological mechanisms. The “No B12” formulation is useful for this research, as B12 itself can affect energy metabolism and exercise performance, and researchers may wish to control for its effects independently.
• Recovery and Muscle Damage: Research into Lipoc (No B12)’s effects on exercise recovery, including muscle damage, inflammation, soreness, and the recovery of strength and performance after exercise. L-carnitine has been shown to reduce exercise-induced muscle damage, inflammation, and soreness, and to speed recovery, potentially through its antioxidant effects, its role in reducing oxidative stress, and its effects on reducing muscle protein breakdown and enhancing muscle protein synthesis. The AOD9604 component’s anti-inflammatory effects (if any) and its effects on reducing fat mass may also contribute to improved recovery. If melanocortin components are included, they may have anti-inflammatory effects that could aid recovery, although they may also cause side effects that could impair recovery. Research using markers of muscle damage (creatine kinase, myoglobin), inflammatory markers (IL-6, TNF-α, CRP), muscle soreness scales, and strength/power testing is investigating the effects of Lipoc (No B12) on exercise recovery and the underlying mechanisms.
• Body Composition for Athletes: Studies investigating Lipoc (No B12) for body composition optimization in athletes, including reducing body fat percentage while preserving or increasing lean muscle mass, achieving target weight classes for combat sports, and improving power-to-weight ratio for endurance and power sports. Athletes often seek to reduce body fat while maintaining or increasing muscle mass to improve performance, but achieving this body composition can be challenging, particularly with aggressive caloric restriction that can lead to muscle loss and performance impairment. Lipoc (No B12)’s selective lipolytic effects (AOD9604), combined with L-carnitine’s fat oxidation-enhancing effects and potential muscle-sparing effects, may allow athletes to reduce body fat while preserving lean muscle mass, potentially with less aggressive caloric restriction than would otherwise be required. Research using DXA, MRI, BIA, and performance testing is investigating the effects of Lipoc (No B12) on body composition and athletic performance, the optimal timing and dosing relative to training and competition, and the potential risks and benefits for athletes. The “No B12” formulation is particularly useful for sports research, as B12 is a common supplement for athletes and may be controlled separately, and researchers may wish to study the effects of the peptide blend independently.

4. Anti-Aging and Longevity Research

Lipoc (No B12) is studied in anti-aging and longevity research for its effects on body composition, metabolic health, and age-related changes:

• Age-Related Body Composition Changes (Sarcopenic Obesity): Research into Lipoc (No B12) for mitigating age-related changes in body composition, particularly sarcopenic obesity—a condition characterized by the simultaneous loss of lean muscle mass (sarcopenia) and accumulation of fat mass (obesity), particularly visceral fat, which is increasingly common in older adults and is associated with significant health risks including functional decline, disability, falls, fractures, type 2 diabetes, cardiovascular disease, and mortality. The AOD9604 component’s selective lipolytic effects may help reduce excess fat mass, particularly visceral fat, without the catabolic effects on muscle that can occur with aggressive weight loss. L-carnitine has been shown to support muscle function, reduce muscle protein breakdown, and potentially improve physical performance in older adults, and may help preserve lean mass during fat loss. The combination of fat reduction and potential muscle preservation may make Lipoc (No B12) particularly useful for research on sarcopenic obesity, where the goal is to reduce fat while preserving or increasing muscle mass and physical function. Research using DXA, MRI, physical function tests (gait speed, chair stand, grip strength), and quality of life measures is investigating the effects of Lipoc (No B12) on body composition and physical function in older adults with sarcopenic obesity.
• Metabolic Health in Aging: Studies investigating Lipoc (No B12)’s potential to improve metabolic health in aging, including insulin sensitivity, glucose tolerance, lipid profiles, hepatic fat, and the prevention of age-related metabolic diseases (type 2 diabetes, metabolic syndrome, cardiovascular disease). Aging is associated with a progressive decline in metabolic health, including increased insulin resistance, impaired glucose tolerance, dyslipidemia, increased visceral and hepatic fat accumulation, and increased prevalence of metabolic syndrome and type 2 diabetes. These age-related metabolic changes are strongly associated with increased visceral fat accumulation, reduced physical activity, and changes in body composition. Lipoc (No B12)’s reduction of visceral and hepatic fat, combined with its potential to improve insulin sensitivity and lipid profiles, may help mitigate age-related metabolic decline and reduce the risk of metabolic diseases in older adults. The “No B12” formulation is useful for this research, as B12 status itself changes with age (B12 deficiency is common in older adults due to reduced stomach acid and malabsorption), and researchers may wish to control for B12 status independently. Research is investigating the effects of Lipoc (No B12) on metabolic health in aging animal models and older adults, and the potential for these metabolic improvements to translate into improved healthspan and longevity.
• Mitochondrial Function and Energy Metabolism: Research into Lipoc (No B12)’s effects on mitochondrial function, energy metabolism, and cellular bioenergetics, which are critical for healthy aging and are known to decline with age. Mitochondrial dysfunction is a hallmark of aging and is implicated in a wide range of age-related diseases, including neurodegeneration, cardiovascular disease, metabolic disorders, and sarcopenia. The L-carnitine component plays a critical role in mitochondrial function by facilitating fatty acid transport into mitochondria for beta-oxidation, and supplementation has been shown to improve mitochondrial function, increase fatty acid oxidation, reduce oxidative stress, and improve cellular bioenergetics in various tissues, particularly in conditions associated with mitochondrial dysfunction. The AOD9604 component’s effects on fat metabolism may also indirectly support mitochondrial function by reducing lipotoxicity and improving substrate availability. Research using mitochondrial function assays (respirometry, ATP production, membrane potential), oxidative stress markers, and gene expression analysis (PGC-1α, TFAM, mitochondrial genes) is investigating the effects of Lipoc (No B12) on mitochondrial function and energy metabolism, and the potential for these effects to contribute to healthy aging and longevity.

Product Specifications

Parameter	Value
Compound Name	Lipoc (No B12) – Lipolytic Peptide Blend
Composition	Specialized blend of lipolytic peptides (typically including AOD9604) and metabolic compounds (including L-carnitine), without added vitamin B12
Key Components	AOD9604 (Tyr-hGH 177-191), L-carnitine, and other lipolytic/metabolic peptides (varies by formulation)
B12 Content	None (No B12 formulation)
Purity/Standardization	Standardized for peptide content and biological activity; each component ≥98% purity
Appearance	White to off-white lyophilized powder
Solubility	Soluble in water, PBS, bacteriostatic water, 0.9% NaCl
pH (1% solution)	5.0 – 7.0
Water Content	≤5% (Karl Fischer)
Endotoxin	<1 EU/mg (LAL method)
Storage	-20°C, sealed, protected from light and moisture
Shelf Life	24 months from date of manufacture

Reconstitution and Handling Guidelines

For optimal results in laboratory research:

1. Allow the vial to equilibrate to room temperature before opening to prevent condensation
2. Reconstitute with bacteriostatic water, sterile water, 0.9% NaCl, or PBS to a desired concentration (typically 1-20 mg/mL total peptide content)
3. Gently swirl or invert the vial until complete dissolution; avoid vigorous shaking, which can cause foaming and peptide degradation
4. For cell culture experiments, filter-sterilize the reconstituted solution using a 0.22 μm filter
5. Aliquot into working volumes to avoid repeated freeze-thaw cycles
6. Store lyophilized powder at -20°C, protected from light; store reconstituted solutions at 2-8°C for short-term use (up to 7 days) or at -20°C for long-term use (up to 3 months), protected from light
7. Avoid exposure to strong proteases, extreme pH, and high temperatures
8. Note: This is a blended formulation; the exact composition may vary by batch, and researchers should refer to the Certificate of Analysis for the specific composition and concentration of each component
9. For in vivo studies: Lipoc (No B12) is typically administered by subcutaneous (SC) or intramuscular (IM) injection, with doses and dosing schedules varying based on the specific formulation, animal model, and research objectives; researchers should optimize dosing based on the individual components and desired effects

Frequently Asked Questions (FAQ)

Q1: What is the difference between Lipoc (No B12) and regular Lipoc (with B12)?

The primary difference between Lipoc (No B12) and regular Lipoc (with B12) is the presence or absence of added vitamin B12 (typically methylcobalamin or cyanocobalamin) in the formulation:
– Regular Lipoc (with B12): Contains the core lipolytic peptide blend (typically including AOD9604, L-carnitine, and other metabolic peptides) plus added vitamin B12. The B12 is included because it plays an essential role in energy metabolism (as a cofactor for methionine synthase and methylmalonyl-CoA mutase), homocysteine regulation, methylation reactions, and neurological function, and may complement the lipolytic and metabolic effects of the other components. B12 deficiency is also common, particularly in older adults, vegans/vegetarians, and individuals with malabsorption, and can cause fatigue, neurological symptoms, and elevated homocysteine, which may counteract the desired metabolic effects.
– Lipoc (No B12): Contains the same core lipolytic peptide blend but without added vitamin B12. This formulation is designed for researchers who: (1) wish to study the effects of the peptide blend independently of B12, to isolate the specific effects of the lipolytic peptides; (2) prefer to control B12 supplementation separately, allowing for precise control of B12 dose and timing; (3) are studying populations or conditions where B12 status needs to be carefully controlled (e.g., B12 deficiency research, homocysteine metabolism studies, drug interaction studies); (4) are using animal models or experimental designs where added B12 might confound the results; (5) prefer to avoid B12 for personal or experimental reasons.
In terms of the core lipolytic and metabolic effects, the two formulations are expected to be similar, as the primary active components (AOD9604, L-carnitine, other peptides) are the same. However, the added B12 in regular Lipoc may provide additional benefits for energy metabolism, homocysteine regulation, and neurological function, particularly in individuals with B12 deficiency or suboptimal B12 status. The “No B12” formulation provides greater experimental control and flexibility, allowing researchers to add B12 separately if desired, at a dose and timing that they control. Researchers should choose the formulation that best fits their specific research objectives and experimental design, and should carefully consider the potential confounding effects of B12 when interpreting results.

Q2: What is the typical composition of Lipoc (No B12)?

The exact composition of Lipoc (No B12) can vary between manufacturers and formulations, as “Lipoc” is a general term for lipolytic peptide blends rather than a single, standardized compound. However, most Lipoc formulations share a common core of lipolytic and metabolic components, typically including:
– AOD9604 (Tyr-hGH 177-191): This is typically the primary lipolytic component, a 16-amino acid peptide fragment of human growth hormone that selectively stimulates lipolysis and inhibits lipogenesis without the growth-promoting or IGF-1-stimulating effects of full-length hGH. It is usually present at a dose of 100-500 mcg per serving/vial.
– L-carnitine: This is a key metabolic component, an amino acid derivative that facilitates the transport of long-chain fatty acids into mitochondria for beta-oxidation (fat burning). It enhances the utilization of fat as an energy source, particularly during exercise, and has antioxidant and mitochondrial-supporting effects. It is usually present at a dose of 100-500 mg per serving/vial (note: L-carnitine is a small molecule, not a peptide, and is present in much larger amounts by weight than the peptide components).
– Additional lipolytic/metabolic peptides (varies by formulation): Some Lipoc formulations may include additional peptides to enhance the lipolytic and metabolic effects, such as:
– Melanotan 2 or related melanocortin peptides: which can reduce appetite, increase energy expenditure, and increase fat oxidation through MC4R receptor activation (note: these can cause significant side effects including flushing, nausea, increased blood pressure, and spontaneous erections)
– Tesamorelin or other GHRH analogs: which stimulate growth hormone release, potentially enhancing lipolysis (note: these increase IGF-1 and may have different side effect profiles)
– Other lipolytic peptides: such as fragments of other hormones or synthetic peptides with lipolytic activity
– Supporting compounds (varies by formulation): Some formulations may include additional metabolic cofactors, antioxidants, or other compounds to support fat metabolism and overall health, such as alpha-lipoic acid, coenzyme Q10, B vitamins (other than B12), or amino acids.
It is important to note that the exact composition, ratios, and doses of each component can vary significantly between different Lipoc products and manufacturers, and researchers should always refer to the product’s Certificate of Analysis (COA) or specification sheet for the exact composition of the specific formulation they are using. When designing experiments, it is critical to know the exact composition and concentration of each component, as this will affect the dosing, interpretation of results, and comparison with other studies. If a specific component is of particular interest, researchers may wish to purchase that component separately and use it as a single-agent control, or to create custom blends with precisely controlled compositions.

Q3: Can Lipoc (No B12) be used in cell culture experiments?

Yes, Lipoc (No B12) can be used in cell culture experiments, although its use is more complex than single compounds due to its blended composition, and researchers should carefully consider the specific research question and appropriate controls. The individual components of Lipoc (No B12) are suitable for cell culture:
– AOD9604: Suitable for cell culture with adipocytes (3T3-L1, 3T3-F442A, primary human adipocytes), hepatocytes (HepG2, primary hepatocytes), and other metabolic cell types. Typical working concentrations range from 1 μg/mL to 100 μg/mL (approximately 0.5-50 μM). It is used to study lipolysis, lipogenesis, adipocyte metabolism, and the mechanisms of growth hormone fragment action.
– L-carnitine: Suitable for cell culture with a wide variety of cell types, including adipocytes, hepatocytes, muscle cells (C2C12, primary myotubes), neurons, and endothelial cells. Typical working concentrations range from 10 μM to 10 mM (physiological concentrations are approximately 5-100 μM in plasma, but higher concentrations are often used in cell culture). It is used to study fatty acid oxidation, mitochondrial function, energy metabolism, oxidative stress, and cellular bioenergetics.
– Additional peptides (if present): Each additional peptide component will have its own suitable cell types, concentrations, and research applications, and researchers should refer to the specific component’s properties.
When using the blended Lipoc (No B12) formulation in cell culture, researchers should:
1. Know the exact composition and concentration of each component (from the COA), and calculate the final concentration of each component in the culture medium.
2. Use appropriate controls, including: (a) individual component controls (AOD9604 alone, L-carnitine alone, each additional peptide alone) at the same concentrations as in the blend, to determine which components are responsible for observed effects; (b) a “vehicle” control (the solvent/buffer used to reconstitute the blend); (c) if studying lipolysis, positive controls (such as isoproterenol or forskolin, which stimulate lipolysis) and negative controls.
3. Consider the potential for interactions between components (synergistic, additive, or antagonistic), which is often the reason for using a blended formulation.
4. Be aware that L-carnitine is present in much higher concentrations (by weight and molarity) than the peptide components, and may dominate some effects, particularly those related to mitochondrial function and fatty acid oxidation.
5. Filter-sterilize the reconstituted solution before adding to cell cultures (if not using pre-sterile solution).
6. Refresh media with fresh Lipoc (No B12) every 24-48 hours for extended experiments, as some peptide components may degrade over time in culture media at 37°C.
In summary, Lipoc (No B12) can be a valuable tool for cell culture research, particularly for studying the combined effects of multiple lipolytic and metabolic compounds on adipose tissue, liver, muscle, and other metabolic cell types. However, due to its blended composition, careful experimental design with appropriate controls is essential to interpret results correctly and to determine the contributions of individual components and any synergistic effects.

Q4: What is the typical dosage range for animal studies and human supplementation?

Dosage of Lipoc (No B12) varies significantly depending on the exact composition of the formulation, the species, the administration route, and the research objective. Since Lipoc is a blended formulation, doses are typically described in terms of the total peptide content or the dose of the primary active component (usually AOD9604). Common dosage ranges include:
– Rodents (acute fat metabolism studies): AOD9604 component at 0.1-10 mg/kg/day (SC/IP), L-carnitine component at 10-500 mg/kg/day (SC/IP/oral), typically administered once or twice daily for 1-4 weeks
– Rodents (chronic obesity/body composition studies): AOD9604 component at 0.5-5 mg/kg/day (SC), L-carnitine component at 50-200 mg/kg/day (oral or SC), typically administered for 4-12 weeks or longer, often in combination with high-fat diet or caloric restriction
– Rodents (exercise/performance studies): AOD9604 component at 0.1-5 mg/kg/day (SC), L-carnitine component at 50-500 mg/kg/day (oral or SC), typically administered for 2-8 weeks, with exercise training
– Rabbits/guinea pigs: AOD9604 component at 0.1-5 mg/kg/day, L-carnitine component at 10-200 mg/kg/day
– Primates: AOD9604 component at 0.01-1 mg/kg/day, L-carnitine component at 1-50 mg/kg/day
– Humans (research/clinical use of individual components):
– AOD9604: 0.1-1 mg (100-1000 mcg) per day, typically administered by subcutaneous injection, often in divided doses (e.g., 250-500 mcg twice daily), for fat loss and body composition
– L-carnitine: 500-3000 mg per day, typically administered orally (or by injection in some clinical settings), for fat metabolism, exercise performance, and recovery
– If melanocortin components are included: doses will be much lower (e.g., Melanotan 2 at 0.25-1 mg per dose, 2-3 times per week) due to their high potency and side effect profile
– For the blended Lipoc (No B12) formulation: The total dose will depend on the specific ratios of components, but typical human use (where legally available for research or clinical use) might involve 1-2 mL per day of a reconstituted solution containing the above doses of each component, administered by subcutaneous injection, often in divided doses (e.g., morning and evening, or pre-exercise).
It is critical to note that:
1. The exact composition of Lipoc (No B12) can vary significantly between products, and researchers should always calculate doses based on the actual concentration of each component in the specific formulation they are using (from the COA).
2. The “No B12” formulation does not contain B12, so researchers studying conditions where B12 status is important should consider adding B12 separately if needed, or should control for B12 status in their experimental design.
3. Doses should be optimized based on the specific animal model, administration route, and study endpoints, and animals/humans should be monitored for any adverse effects.
4. If the formulation contains melanocortin peptides (such as Melanotan 2), researchers should be aware of the significant side effect profile of these compounds (flushing, nausea, vomiting, increased blood pressure, spontaneous erections, increased heart rate) and should use appropriate doses and monitoring.
5. For human use, researchers should comply with all applicable laws, regulations, and ethical guidelines, and should note that Lipoc formulations may not be approved for human use in all jurisdictions.

Q5: How does Lipoc (No B12) compare to other lipolytic peptides and fat loss compounds?

Lipoc (No B12) is one of several approaches to lipolysis and fat loss, each with distinct mechanisms, efficacy, and safety profiles:
– vs. AOD9604 alone: Lipoc (No B12) typically includes AOD9604 as its primary lipolytic component, but adds L-carnitine and potentially other peptides to enhance fat oxidation, energy metabolism, and overall fat loss. AOD9604 alone provides selective lipolysis without the growth-promoting effects of hGH, but does not directly enhance fatty acid oxidation or mitochondrial function. The addition of L-carnitine in Lipoc ensures that the free fatty acids released by AOD9604-induced lipolysis are efficiently transported into mitochondria for oxidation, potentially producing greater net fat loss than AOD9604 alone. The blended formulation may also provide additional benefits for energy metabolism, exercise performance, and recovery.
– vs. Full-length human growth hormone (hGH): Full-length hGH is a potent lipolytic agent that also stimulates IGF-1 production, promotes linear growth, increases lean mass, and can cause significant side effects including insulin resistance, glucose intolerance, edema, joint pain, carpal tunnel syndrome, and acromegaly with long-term use. Lipoc (No B12)’s primary lipolytic component (AOD9604) is a small fragment of hGH that selectively retains the lipolytic effects without the growth-promoting, IGF-1-stimulating, or diabetogenic effects of full-length hGH. The addition of L-carnitine further enhances fat oxidation. Thus, Lipoc (No B12) may provide the fat-burning benefits of hGH with a much more favorable safety profile and fewer systemic side effects, although it may not have the muscle-building or anti-aging effects of full-length hGH.
– vs. Melanotan 2 alone: Melanotan 2 is a potent melanocortin agonist that reduces appetite, increases energy expenditure, and promotes fat loss, but also causes significant side effects including flushing, nausea, vomiting, increased blood pressure, increased heart rate, spontaneous erections, and skin darkening (tanning). If Lipoc (No B12) includes melanocortin components, they are typically present at lower doses or in combination with other peptides to potentially reduce side effects while maintaining efficacy. If Lipoc does not include melanocortin components, it will have a different mechanism (primarily peripheral lipolysis via AOD9604 + fat oxidation via L-carnitine) with fewer central side effects, but may be less potent for overall weight loss (since it does not significantly reduce appetite).
– vs. GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide): GLP-1 receptor agonists and dual/triple agonists are highly effective for weight loss, primarily through appetite suppression and slowed gastric emptying, with additional metabolic benefits for glucose control and cardiovascular health. They are approved for clinical use in obesity and type 2 diabetes, but can cause significant gastrointestinal side effects (nausea, vomiting, diarrhea, constipation) and are expensive. Lipoc (No B12) has a different mechanism (primarily peripheral lipolysis and fat oxidation, with minimal appetite suppression unless melanocortin components are included) and may have fewer gastrointestinal side effects, but is likely less potent for overall weight loss than GLP-1 agonists. It may be useful as an adjunct to GLP-1 agonists or for individuals who cannot tolerate GLP-1 side effects.
– vs. L-carnitine alone: L-carnitine alone enhances fatty acid transport into mitochondria and can increase fat oxidation, particularly during exercise, but does not directly stimulate lipolysis (breakdown of stored fat). Its effects on overall fat loss are generally modest, particularly in individuals with adequate carnitine status. Lipoc (No B12) combines L-carnitine with AOD9604 (which stimulates lipolysis, releasing free fatty acids) and potentially other peptides, creating a more comprehensive approach to fat metabolism that may produce greater net fat loss than L-carnitine alone.
– vs. Stimulant-based fat burners (caffeine, ephedrine, synephrine): Stimulant-based fat burners primarily work by increasing energy expenditure, thermogenesis, and lipolysis through sympathetic nervous system activation (beta-adrenergic receptors). They can be effective for fat loss but can cause significant side effects including tachycardia, hypertension, anxiety, insomnia, jitteriness, and in rare cases, serious cardiovascular events. Lipoc (No B12) has a different mechanism (peptide-mediated lipolysis + carnitine-mediated fat oxidation) with minimal stimulant effects, and may have a more favorable cardiovascular and side effect profile, particularly for individuals who are sensitive to stimulants or have cardiovascular risk factors.
In summary, Lipoc (No B12) offers a unique multi-target approach to fat metabolism, combining peptide-mediated lipolysis (AOD9604) with enhanced fatty acid oxidation (L-carnitine) and potentially other metabolic peptides, with a mechanism and side effect profile distinct from other fat loss approaches. Its blended composition allows for potential synergistic effects between components, and the “No B12” formulation provides greater experimental control and flexibility. Researchers should consider the specific research objectives, desired mechanisms, and safety considerations when choosing between Lipoc (No B12) and other lipolytic approaches.

Q6: Is Lipoc (No B12) stable in solution?

Lipoc (No B12) is a blended formulation, and its stability in solution depends on the stability of its individual components, primarily the peptide components (AOD9604 and any other peptides) and L-carnitine. L-carnitine is a small, highly stable molecule that is very stable in solution, so the stability of the blended formulation is primarily determined by the stability of the peptide components.
– Lyophilized powder: Lipoc (No B12) in lyophilized form is stable for 24 months when stored at -20°C, protected from light and moisture. The lyophilized form is the preferred storage format for long-term storage, as it minimizes peptide degradation and microbial growth.
– After reconstitution: Reconstituted Lipoc (No B12) solutions are stable for approximately 7-14 days when stored at 2-8°C (refrigerated), protected from light, particularly when reconstituted in bacteriostatic water (containing 0.9% benzyl alcohol) to inhibit microbial growth. For long-term storage, reconstituted solutions should be aliquoted, protected from light, and stored at -20°C or -80°C, where they remain stable for up to 3 months.
– Freeze-thaw cycles: Avoid repeated freeze-thaw cycles, as these can cause peptide degradation, aggregation, and loss of biological activity. Aliquoting reconstituted solutions into single-use volumes is recommended to minimize freeze-thaw cycles.
– Light sensitivity: The peptide components (particularly if they contain tryptophan, tyrosine, or other light-sensitive amino acids) may be sensitive to light, and solutions should be protected from light during storage and experiments. AOD9604 does not contain tryptophan but does contain tyrosine, which is moderately light-sensitive.
– pH stability: The peptide components are generally stable at neutral to slightly acidic pH (pH 4-7), but are less stable at strongly acidic (pH <3) or strongly alkaline (pH >9) conditions, which can cause peptide degradation (hydrolysis, deamidation, oxidation). L-carnitine is stable across a wide pH range.
– Temperature: At room temperature, reconstituted Lipoc (No B12) is stable for approximately 1-3 days (protected from light), but refrigeration is recommended for longer storage. At 37°C (cell culture conditions), the peptide components may degrade over time (due to proteases, thermal instability, and oxidation), and media should be refreshed every 24-48 hours for extended cell culture experiments.
– Proteases: The peptide components are sensitive to degradation by proteases, and solutions should be protected from protease contamination (e.g., by using sterile technique, bacteriostatic water, and protease inhibitors if necessary for specific experiments).
– Oxidation: Peptides containing cysteine, methionine, or other oxidizable amino acids may be susceptible to oxidation. AOD9604 contains two cysteine residues (forming a disulfide bond) and is moderately susceptible to oxidation; solutions should be protected from strong oxidizing agents and excessive air exposure.
Note that because Lipoc (No B12) is a blended formulation, the stability of each component should be considered, and the overall stability of the blend will be determined by the least stable component. For critical experiments, researchers may wish to verify the stability and biological activity of the reconstituted solution over time, or to prepare fresh solutions for each experiment. The high stability of the lyophilized powder makes it convenient for long-term storage, and researchers are encouraged to store the material in lyophilized form and reconstitute only the amount needed for immediate use, always protecting from light and using aseptic technique to prevent microbial contamination.

Q7: Can Lipoc (No B12) be used in combination with other peptides or treatments?

Yes, Lipoc (No B12) is frequently used in combination with other agents in research and therapeutic settings, and some of the most common combinations include:
– Combination with vitamin B12 (methylcobalamin or cyanocobalamin): Since Lipoc (No B12) does not contain added B12, researchers may choose to add B12 separately, at a dose and timing they control, to study the effects of the peptide blend + B12 combination. B12 plays an essential role in energy metabolism, homocysteine regulation, methylation reactions, and neurological function, and may complement the lipolytic and metabolic effects of Lipoc. This combination is particularly useful for researchers who want to study the specific contribution of B12 to the overall effects, or who want to use a different form or dose of B12 than what is typically included in regular Lipoc formulations.
– Combination with growth hormone-releasing peptides (GHRPs: ipamorelin, hexarelin, GHRP-6) or GHRH analogs (sermorelin, CJC-1295, tesamorelin): Used for body composition research, combining Lipoc’s lipolytic and fat oxidation effects with the growth hormone-releasing and potential muscle-building effects of GHRPs/GHRH analogs. This combination may provide additive or synergistic effects on body composition (fat loss + potential lean mass gain), but may also increase side effects due to increased hGH/IGF-1 levels (insulin resistance, edema, joint pain). Researchers should carefully monitor for these effects and consider whether the AOD9604 component’s lack of IGF-1 stimulation is a desired feature that may be offset by the addition of GHRPs/GHRH analogs.
– Combination with melanocortin peptides (Melanotan 2, PT-141/bremelanotide, setmelanotide): If Lipoc (No B12) does not already include melanocortin components, researchers may add them separately to combine the peripheral lipolytic effects of Lipoc with the central appetite-suppressing and energy expenditure-increasing effects of melanocortin agonists. This combination may produce greater overall weight loss through complementary mechanisms (peripheral fat breakdown + central appetite reduction), but may also increase side effects (flushing, nausea, increased blood pressure, spontaneous erections). If Lipoc already includes melanocortin components, adding more may increase side effects without proportional benefit.
– Combination with GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide): Used for obesity and metabolic research, combining Lipoc’s peripheral lipolytic/fat oxidation effects with GLP-1 agonists’ appetite-suppressing and insulin-sensitizing effects. This combination may provide additive or synergistic effects on weight loss, body composition, and metabolic health, and may allow for lower doses of GLP-1 agonists (reducing gastrointestinal side effects). This is a particularly promising combination for obesity research, as it targets multiple pathways involved in energy balance and fat metabolism.
– Combination with exercise and/or caloric restriction: As discussed in the research applications section, Lipoc (No B12) is often combined with diet and/or exercise for enhanced fat loss and body composition optimization. The peptide blend may enhance the fat-burning effects of exercise (by increasing lipolysis and fatty acid oxidation) and may help preserve lean mass during caloric restriction. This is the most common and evidence-based combination for body composition research.
– Combination with other metabolic cofactors: Researchers may combine Lipoc (No B12) with other metabolic cofactors such as alpha-lipoic acid (antioxidant, enhances insulin sensitivity, increases fat oxidation), coenzyme Q10 (mitochondrial function, antioxidant), B vitamins (B2, B3, B5, B6 – all involved in energy metabolism), magnesium (cofactor for many metabolic enzymes), or chromium (insulin sensitivity). These combinations are used to study the effects of comprehensive metabolic support on fat metabolism, energy production, and overall metabolic health.
– Combination with other lipolytic peptides: Researchers may combine Lipoc (No B12) with other lipolytic peptides such as tesamorelin (GHRH analog, approved for HIV-associated lipodystrophy), growth hormone (full-length, for comparison), or other experimental lipolytic compounds, to study potential synergistic effects or to compare mechanisms of action.
Researchers should carefully design combination studies, including appropriate controls for each agent alone and in combination, to assess synergistic, additive, or antagonistic effects. Note that Lipoc (No B12) is generally well-tolerated, but combination with other agents may increase the risk of adverse effects, particularly when combined with hGH/IGF-1-stimulating peptides (insulin resistance, edema) or melanocortin peptides (flushing, nausea, cardiovascular effects). Researchers should consult relevant literature for information on potential interactions and should monitor relevant safety parameters when using Lipoc (No B12) in combination with other agents. The “No B12” formulation is particularly useful for combination studies, as it allows researchers to precisely control B12 status and to add B12 separately if desired, without the confounding effects of pre-added B12 in the formulation.

Related Research Compounds

Researchers studying Lipoc (No B12) often explore these complementary compounds:

• AOD9604 – The primary lipolytic component of Lipoc, a growth hormone fragment with selective fat-burning effects
• L-Carnitine – Amino acid derivative that facilitates fatty acid transport into mitochondria for oxidation
• Vitamin B12 (Methylcobalamin) – Essential vitamin for energy metabolism, homocysteine regulation, and neurological function (often added separately to the No B12 formulation)
• Melanotan 2 (MT-2) – Melanocortin agonist with appetite-suppressing and energy expenditure-increasing effects (sometimes included in Lipoc formulations)
• Ipamorelin – Selective GHRP that stimulates growth hormone release, used in combination for body composition
• Sermorelin Acetate – GHRH analog that stimulates growth hormone release, used in combination for body composition
• Semaglutide – GLP-1 receptor agonist with potent appetite-suppressing and weight loss effects, used in combination for obesity
• Tirzepatide – Dual GLP-1/GIP agonist with remarkable weight loss efficacy, used in combination for obesity
• Alpha-Lipoic Acid – Antioxidant and metabolic cofactor, used in combination for insulin sensitivity and fat oxidation
• BPC-157 – 15-amino acid peptide with cytoprotective and healing effects, sometimes used in combination for recovery

Quality Assurance

Our Lipoc (No B12) is manufactured under strict conditions and undergoes comprehensive quality testing:

• Each individual component is tested for purity (≥98% by HPLC) and identity (mass spectrometry)
• Final blend is tested for peptide content (Lowry/BCA method), amino acid profile, and L-carnitine content
• Mass spectrometry verification of each peptide component (confirming molecular weight and correct sequence)
• Amino acid analysis (verifying the presence and ratios of amino acids from peptide components and L-carnitine)
• HPLC purity analysis of the final blend (verifying component ratios and detecting impurities)
• Biological activity verification (in vitro lipolysis assay in 3T3-L1 adipocytes, fatty acid oxidation assay)
• B12 content verification (confirming no detectable B12 in the No B12 formulation)
• pH testing (5.0-7.0 for 1% solution)
• Water content determination (Karl Fischer, ≤5%)
• Endotoxin testing (LAL method, <1 EU/mg)
• Microbial contamination screening (bioburden, yeast/mold)
• Residual solvent testing
• Heavy metal testing
• Stability testing under various storage conditions

Each batch is accompanied by a Certificate of Analysis (COA) detailing the exact composition, concentration of each component, purity, and all test results. We maintain complete batch records for full traceability and regulatory compliance. Custom formulations (including different ratios of components, addition or removal of specific peptides, custom concentrations, and combination products) are available upon request. We also offer custom peptide synthesis and formulation services for researchers requiring specific lipolytic blends, metabolic peptide combinations, or related compounds for body composition and metabolic research.

Important Disclaimer

FOR RESEARCH USE ONLY. This product is intended exclusively for laboratory and scientific research purposes. It is not approved for human consumption, clinical diagnosis, therapeutic treatment, or veterinary use in all jurisdictions, and has not been evaluated by the FDA or other regulatory authorities for therapeutic use. Lipoc (No B12) is a biologically active peptide blend with significant effects on fat metabolism, body composition, energy metabolism, and potentially other physiological systems; all experiments must be conducted by qualified researchers in accordance with institutional biosafety guidelines, animal care protocols, and applicable regulations. Purchasers assume full responsibility for proper handling, storage, and use of this research material. This product is not intended for self-administration or use outside of approved research settings. Researchers should note that Lipoc (No B12) is generally considered safe and well-tolerated, but may cause side effects in some individuals, including injection site reactions (pain, redness, swelling, itching), headache, dizziness, nausea, vomiting, diarrhea, constipation, abdominal pain, fatigue, insomnia, changes in appetite, changes in body weight, changes in blood glucose (minimal with AOD9604, but possible with other components), changes in blood pressure (if melanocortin components are included), flushing, sweating, muscle cramps, joint pain, water retention, allergic reactions (rash, itching, urticaria, anaphylaxis in rare cases), and in rare cases, more serious adverse effects. If the formulation contains melanocortin peptides (such as Melanotan 2), additional side effects may include spontaneous erections or sexual arousal, yawning, stretching, increased body temperature, darkening of skin or moles, nausea, vomiting, flushing, increased blood pressure, and increased heart rate. Individuals with pre-existing medical conditions (particularly type 1 diabetes, pancreatitis, gallbladder disease, severe kidney or liver disease, cardiovascular disease, hypertension, bleeding disorders, cancer history, pituitary/hypothalamic disorders, or known allergies to any component of the formulation) should exercise extreme caution, and Lipoc (No B12) should be used under medical supervision in pregnant or breastfeeding women (although the individual components are generally considered safe, the blended formulation has not been studied in pregnancy). In vivo studies should be conducted with appropriate ethical review and careful monitoring of relevant physiological parameters, including body weight, body composition, food intake, blood glucose, insulin, lipid profiles, liver enzymes, kidney function, blood pressure, heart rate, and any behavioral or adverse effects. The use of Lipoc (No B12) for weight loss, bodybuilding, performance enhancement, anti-aging, or other non-research purposes is not endorsed, and individuals seeking lipolytic or body composition treatments for health reasons should consult with a qualified healthcare provider to determine whether any treatment is appropriate for their condition, and to ensure that any products used are obtained from reputable sources and used under proper medical supervision. Researchers should be aware of the regulatory and ethical considerations surrounding the use of lipolytic peptides and blended formulations in both research and potential clinical settings, and should conduct studies in accordance with all applicable laws, regulations, and institutional guidelines. Note: The exact composition of Lipoc (No B12) can vary between manufacturers and formulations, and researchers should always refer to the product’s Certificate of Analysis for the exact composition and concentration of each component in the specific formulation they are using.